Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC Vaccine and TMZ for Newly-diagnosed Glioblastoma After Surgery
NCT04968366Phase 1Completed
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jul 2021
- Primary completion
- Apr 2024
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous dendritic cell vaccine in glioblastoma (GBM), sponsored by Beijing Tiantan Hospital. Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started Jul 2021; status: completed.
02
Drugs
autologous dendritic cell vaccine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04968366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04968366.